Skip to main content

"Generation and Evaluation of ""Next-generation"" Antibody-Toxin-Conjugates for Cancer Therapy"

Ziel

Therapeutic antibodies have transformed cancer therapy during the last decade, due to their high selectivity of targeting cancer cells in comparison to standard small molecule chemotherapy. Most recently, the coupling of cellular toxins to therapeutic antibodies has demonstrated an even greater efficacy in the therapy of cancer and the first, highly potent antibody drug conjugate (ADC), Adcetris®, was FDA approved in August 2011.
All ADCs currently in clinical development are generated by chemical conjugation of small molecule toxins to antibodies. This is an inefficient process, as site and ratio of toxin coupling cannot be controlled. In addition, the chemical conjugation involves chemical modification of potentially functional parts of the antibody. This can have negative effects on stability, specificity, CMC properties and the overall structure of the antibody. All this renders ADC manufacturing highly challenging, complicates regulatory procedures, and adds to development time and costs.
The SME consortium has complementary proprietary technologies and proposes to leverage this complementary expertise and know-how for defining novel processes of enzymatically conjugating small molecule toxins to antibodies that allow full control about toxin coupling site and ratio. Due to the high selectivity of enzymatic conjugation and physiologic conjugation conditions, it is expected that more homogeneous ADCs are generated with better CMC properties, higher potency, and at lower cost-of-goods in manufacturing. The consortium members believe that this represents a disruptive technology that will be highly competitive to traditional chemical conjugation, currently dominated by U.S.-based ADC technology companies Seattle Genetics and Immunogen. In addition to novel composition-of-matter IP, important novel know-how for ADC development will be created. Most importantly, better quality and potency of these “next-generation” ADCs will eventually benefit cancer patients.

Aufforderung zur Vorschlagseinreichung

FP7-SME-2013
Andere Projekte für diesen Aufruf anzeigen

Koordinator

NBE-THERAPEUTICS AG
Adresse
Hochbergerstrasse 60c Technologie Park Basel
4057 Basel
Schweiz

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Ulf Grawunder (Dr.)
EU-Beitrag
€ 422 380

Beteiligte (11)

ERA BIOTECH

Beteiligung beendet

Spanien
EU-Beitrag
€ 171 758,16
Adresse
Calle Baldiri Reixac 15-21
08028 Barcelona

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Miriam Bastida (Dr.)
TUBE PHARMACEUTICALS GMBH
Österreich
EU-Beitrag
€ 276 615
Adresse
Leberstrasse 20
1110 Wien

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Wolfgang Richter (Dr.)
EVITRIA AG
Schweiz
EU-Beitrag
€ 14 540
Adresse
Wagistrasse 25-27
8952 Schieren

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Markus Hildinger (Dr.)
PROTAGEN PROTEIN SERVICES GMBH
Deutschland
EU-Beitrag
€ 16 040
Adresse
Otto Hahn Strasse 15
44227 Dortmund

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Martin Blueggel (Dr.)
CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH
Deutschland
EU-Beitrag
€ 12 760
Adresse
Am Flughafen 12-14
79108 Freiburg

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Silvia Naus (Dr.)
Westfälische Wilhelms-Universität Münster

Beteiligung beendet

Deutschland
Adresse
Schlossplatz 2
48149 Muenster

Auf der Karte ansehen

Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Katharina Steinberg (Dr.)
JPT PEPTIDE TECHNOLOGIES GMBH
Deutschland
EU-Beitrag
€ 8 800
Adresse
Volmerstrasse 5 Utz
12489 Berlin

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Karsten Schnatbaum (Dr.)
BIOMEDAL SL
Spanien
EU-Beitrag
€ 8 800
Adresse
Cuba 1-1b
41100 Sevilla

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Angel Cebolla (Dr.)
TBD-BIODISCOVERY OU
Estland
EU-Beitrag
€ 7 590
Adresse
Tiigi 61b
50410 Tartu

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Olga Tsubrik (Dr.)
INNO TUNE BVBA
Belgien
EU-Beitrag
€ 9 040
Adresse
Voorhoutkaai 20
9000 Gent

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Lieven De Smedt (Mr.)
ZERA INTEIN PROTEIN SOLUTIONS SL
Spanien
EU-Beitrag
€ 112 676,84
Adresse
Cavallers 50
Barcelona

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Miriam Bastida (Dr.)